EUCTR2009-018102-22-FR进行中（未招募）1 期
A multicentre, open-label, repeated-dose, pharmacokinetic study of Propranolol in infants treated for proliferating infantile hemangiomas (IHs) requiring systemic therapy.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •A patient will be eligible if he/she meets all of the following criteria:
- •Written informed consent(s) for study participation is obtained according to national regulations from the patient’s parent(s) or guardian(s) prior to performing any study procedures,
- •The patient is 35 to 150 days old, inclusive, at inclusion,
- •Proliferating IH (target hemangioma) requiring systemic therapy is present: function-threatening IH, IH in certain anatomic locations that often leave permanent scars or deformity, large facial IH, smaller IH in exposed areas, severe ulcerated IH, pedunculated IH,
- •Affiliated with, or beneficiary of the social security.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A patient will be ineligible if he/she meets any of the following criteria:
- •The patient has a medically unstable health status that may interfere with his/her ability to complete the study,
- •The patient presents with one or more of the following medical conditions: Congenital hemangioma; Kasabach-Merritt syndrome; bronchial asthma; bronchospasm; hypoglycaemia (< 40 mg/dl or at risk); untreated phaeochromocytoma; hypotension (< 50/30); second or third degree heart block; cardiogenic shock; metabolic acidosis; bradycardia (< 80 bpm); severe peripheral arterial circulatory disturbances; Raynaud’s phenomenon; sick sinus syndrome; uncontrolled heart failure or Prinzmetal’s angina; documented PHACES syndrome with central nervous system involvement,
- •The patient (and/or the mother if she is breastfeeding the patient) has received at least one of the following prohibited medications within 15 days of randomisation:
- •o Anaesthetic agents (the exclusion period is shortened to 48 hours, if anaesthesia has been performed for diagnosis investigation (e.g. MRI…)
- •o Cardiovascular treatments: anti-arrhythmics, calcium channel blockers, ACE inhibitors, inotropic agents, vasodilators (hydralazine hydrochloride…), clonidine…
- •o Hypoglycaemic agents or drugs able to induce hypoglycaemia
- •o Anti-ulcer drugs (cimetidine…)
- •o Metoclopramide
- •o Prostaglandin synthetase inhibitors
- •o Sympathomimetic agents and parenteral adrenaline
- •o Benzodiazepines
- •o Neuroleptic drugs (chlorpromazine, sultopride hydrochloride…)
- •o Other drugs: triptans, ergotamine, theophylline, warfarin, thyroxine, floctafenine,
- •The patient (and/or the mother if she is breastfeeding the patient) has received any treatment which could lead to induction or inhibition of hepatic microsomal enzymes within 2 months of randomisation,
- •The patient has previously been administered at least one of the following prohibited medications: systemic (oral, intra-venous or intra-muscular), intra-lesional or topical corticosteroids, imiquimod, vincristine, alfa-interferon, Propranolol or other beta-blockers,
- •The patient has previously been treated for IH, including any surgical and/or medical procedures (e.g. laser therapy),
- •The patient’s mother has been breastfeeding the patient while she was also being treated with beta-blockers (including Propranolol ) or, she has been breastfeeding the patient within 15 days of randomisation while she was also being treated with systemic (oral, intra-venous or intra-muscular) corticosteroids, vincristine or alfa-interferon,
- •The patient is known to have a hypersensitivity to Propranolol or to any component of the investigational product and/or any other beta-blockers,
- •The patient has previously experienced an anaphylactic reaction,
- •The patient has a life-threatening IH,
- •Diagnosis of the soft tissue tumour as IH is not clinically certain, particularly in the case of sub-dermal lesions,
- •The patient was born prematurely and has not yet reached his/her term equivalent age (e.g. an infant born 2 months prematurely cannot be included before the age of 2 months),
- •LVEF (left ventricular
研究者
相似试验
进行中（未招募）
不适用
A Multi-center, open-label, multiple dose, dose finding study exploring the safety and tolerability of Beraprost Sodium Modified Release in PAH patientsPulmonary Arterial HypertensionMedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2008-003290-41-IEungRx10
进行中（未招募）
不适用
A Multi-center, open-label, multiple dose, dose finding study exploring the safety and tolerability of Beraprost Sodium Modified Release in PAH patientsMedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionPulmonary Arterial HypertensionEUCTR2008-003290-41-BEung Rx20
已完成
1 期
Bioequivalence study comparing felbamate tablets USP 600 mg of Emcure Pharmaceuticals Ltd., India to the Reference Listed Drug (RLD), Felbatol® (felbamate) 600 mg tablets manufactured by MEDA Pharmaceuticals Inc, USA in adult male and nonpregnant female epilepsy patients.CTRI/2015/08/006138Emcure Pharmaceuticals Ltd28
进行中（未招募）
1 期
Study of recombinant factor VIIa fusion protein (rVIIa-FP, CSL689) for on-demand treatment of bleeding episodes in patients with hemophilia A or B with inhibitors.Hemophilia A with inhibitors, Hemophilia B with inhibitorsMedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 100000004850EUCTR2012-001309-26-DECSL Behring GmbH54
进行中（未招募）
1 期
Study of recombinant factor VIIa fusion protein (rVIIa-FP, CSL689) for on-demand treatment of bleeding episodes in patients with hemophilia A or B with inhibitors.Hemophilia A with inhibitors, Hemophilia B with inhibitorsMedDRA version: 18.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850MedDRA version: 18.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 100000004850EUCTR2012-001309-26-ESCSL Behring GmbH54